Bioinformatics Market Size, Share, Growth, and Industry Analysis, By Type (Knowledge Management Tools, Bioinformatics Platform, Bioinformatics Services), By Application (Metabolomics, Molecular Phylogenetics, Transcriptomics, Proteomics, Chemoinformatics, Genomics, Others), Regional Insights and Forecast to 2035

Bioinformatics Market Overview

Bioinformatics Market size, valued at USD 12572.91 million in 2026, is expected to climb to USD 40913.27 million by 2035 at a CAGR of 14.01%.

The Bioinformatics market is expanding rapidly due to increasing genomic sequencing volumes, precision medicine programs, and AI-integrated healthcare research. More than 42 million genomic datasets were processed globally during 2025, while over 68% of pharmaceutical companies adopted bioinformatics platforms for drug discovery workflows. Cloud-based bioinformatics deployment crossed 59% adoption among biotechnology laboratories. Sequencing throughput improved by 31% between 2023 and 2025, reducing computational turnaround time to less than 18 hours for large-scale genome analysis. More than 74% of clinical research organizations integrated bioinformatics analytics into oncology studies. Protein structure prediction platforms handled over 9 million datasets annually, while transcriptomic studies increased by 27% across research institutions worldwide.

The United States accounted for nearly 39% of global bioinformatics activity during 2025 due to high genomic testing adoption and extensive biotechnology research infrastructure. More than 2,900 biotechnology firms in the U.S. utilized bioinformatics software for clinical data interpretation. Around 71% of precision medicine initiatives in the country integrated cloud-based genomic analysis tools. Over 4.2 million genome sequencing procedures were conducted in U.S. laboratories during 2024. National Institutes of Health funding for computational biology projects exceeded support for 12,000 active research programs. More than 63% of hospitals conducting oncology diagnostics adopted bioinformatics workflows, while AI-supported drug target identification platforms improved screening efficiency by 34% in pharmaceutical research centers.

Download Free Sample to learn more about this report.

Key Findings

• Key Market Driver: More than 72% adoption of genomic sequencing, 64% integration of AI analytics, 58% increase in clinical data processing.
• Major Market Restraint: Around 47% of healthcare organizations report cybersecurity concerns, 41% face interoperability limitations, 38% encounter high computational infrastructure costs.
• Emerging Trends: Nearly 69% of laboratories adopted cloud bioinformatics, 57% increased AI-driven predictive analytics usage, 46% expanded multi-omics integration.
• Regional Leadership: North America held approximately 39% market share, Europe accounted for 28%, Asia-Pacific represented 24%.
• Competitive Landscape: Over 61% of industry competition is concentrated among global biotechnology firms, while 54% of companies prioritize AI integration, 43% focus on cloud deployment.
• Market Segmentation: Genomics applications represented nearly 34% share, proteomics accounted for 18%, transcriptomics reached 16%, chemoinformatics held 11%.
• Recent Development: During 2023-2025, more than 44% of manufacturers launched AI-enabled platforms, 39% expanded cloud sequencing services.

Bioinformatics Market Latest Trends

Artificial intelligence integration has become one of the strongest trends in the bioinformatics market, with more than 67% of sequencing laboratories implementing machine learning algorithms for genomic interpretation during 2025. Automated genome annotation platforms reduced manual analysis time by 43%, while cloud-based data storage adoption reached 59% among biotechnology companies. Multi-omics analysis platforms increased utilization by 48% because researchers are combining genomics, proteomics, and metabolomics datasets to improve disease understanding. Over 51% of pharmaceutical organizations adopted predictive analytics tools to accelerate biomarker discovery and drug target validation.

Precision medicine research continues to stimulate innovation in bioinformatics infrastructure. More than 4.8 million oncology sequencing tests were analyzed globally during 2024, while 62% of cancer research institutions implemented advanced genomic databases for mutation tracking. Single-cell sequencing studies increased by 36% due to growing demand for cellular-level disease profiling. AI-supported protein structure modeling platforms processed over 8 million protein datasets annually. Approximately 57% of hospitals involved in rare disease diagnostics integrated bioinformatics software into clinical decision systems. In addition, edge computing adoption within bioinformatics workflows increased by 24%, enabling faster data processing in decentralized laboratory environments and improving real-time diagnostics accuracy by 29%.

Bioinformatics Market Dynamics

DRIVER

"Rising demand for precision medicine and genomic sequencing"

The increasing demand for precision medicine is significantly driving the bioinformatics market. More than 74% of oncology treatment programs globally rely on genomic analysis for therapy selection. Genome sequencing costs declined by 32% between 2022 and 2025, encouraging broader adoption across hospitals and research centers. Over 6.3 million next-generation sequencing tests were conducted worldwide during 2024. Pharmaceutical companies increased genomic data utilization by 53% to identify biomarkers and optimize drug discovery pipelines. Nearly 61% of clinical trials integrated bioinformatics-based patient stratification methods. Rare disease diagnosis accuracy improved by 41% due to advanced genomic interpretation software. Government-funded genomic programs expanded by 37% across developed countries, while AI-assisted sequencing interpretation reduced diagnostic turnaround time by 28%. Increasing demand for personalized healthcare and targeted therapeutics continues to expand computational biology applications globally.

RESTRAINT

"Data privacy concerns and high infrastructure complexity"

Bioinformatics platforms process massive volumes of sensitive genomic information, creating substantial cybersecurity and compliance concerns. Nearly 47% of healthcare institutions reported difficulties maintaining genomic data privacy during cloud-based analysis. Over 39% of biotechnology companies encountered integration challenges with legacy laboratory systems. High-performance computing infrastructure costs increased operational expenditure for 42% of research organizations. Data storage requirements for genomic sequencing expanded by 58% between 2023 and 2025, increasing pressure on computational resources. Around 33% of laboratories faced shortages of trained bioinformatics analysts and computational biologists. Regulatory variations across countries affected 29% of multinational genomic studies, delaying clinical implementation timelines. More than 35% of smaller biotechnology firms reported difficulty scaling AI-enabled analytics systems due to limited technical expertise and infrastructure capacity.

OPPORTUNITY

"Expansion of AI-driven drug discovery and multi-omics research"

AI-enabled bioinformatics platforms are creating major opportunities across pharmaceutical and biotechnology industries. More than 63% of drug discovery companies adopted predictive genomic analytics to improve compound screening accuracy. Multi-omics integration projects increased by 46% during 2025 because researchers increasingly combine transcriptomic, proteomic, and metabolomic datasets. AI-assisted protein structure prediction improved biological target identification efficiency by 38%. Over 52% of biotechnology startups invested in cloud-native bioinformatics platforms to support decentralized research collaboration. Synthetic biology projects utilizing bioinformatics tools expanded by 34% globally. Agricultural genomics programs increased computational biology investment by 29% to improve crop resilience and genetic optimization. Real-time genomic surveillance platforms processed more than 11 million pathogen datasets during 2024, creating opportunities in infectious disease monitoring and public health research.

CHALLENGE

"Managing large-scale biological data and interoperability issues"

Handling extremely large biological datasets remains a major challenge for the bioinformatics market. Global genomic databases exceeded 45 exabytes of biological information during 2025, creating scalability concerns for research institutions. Nearly 44% of laboratories experienced compatibility issues between sequencing instruments and analytics software platforms. Data transfer delays affected 31% of cloud-based genomic projects because of insufficient bandwidth infrastructure. More than 36% of organizations struggled with standardizing multi-omics datasets across research environments. Computational analysis time for complex genomic studies increased by 27% due to higher sequencing depth requirements. Approximately 40% of research collaborations reported difficulties integrating cross-border healthcare datasets because of inconsistent regulatory standards. In addition, software validation requirements delayed deployment timelines for 25% of clinical bioinformatics platforms used in diagnostic applications.

Bioinformatics Market Segmentation

Download Free Sample to learn more about this report.

By Type

Knowledge Management Tools: Knowledge management tools accounted for nearly 22% of the bioinformatics market during 2025 due to increasing biological database management requirements. More than 61% of research institutions adopted centralized genomic data repositories for secure information storage. These tools processed over 14 million biological records annually, including DNA sequences, protein structures, and clinical datasets. Around 53% of academic laboratories integrated automated annotation software to improve research efficiency. AI-supported biological indexing improved dataset retrieval speed by 36%. Pharmaceutical firms increased investment in biological knowledge management systems by 31% to support collaborative drug discovery. Cloud-based biological database adoption reached 48% among biotechnology companies. Increasing demand for real-time genomic information sharing and secure clinical data handling continues to strengthen the adoption of knowledge management tools globally.

Bioinformatics Platform: Bioinformatics platforms represented approximately 46% market share because of extensive demand for integrated genomic analysis solutions. More than 72% of sequencing laboratories implemented end-to-end bioinformatics platforms for data interpretation and workflow automation. These systems analyzed over 42 million genomic datasets globally during 2025. AI-enhanced analytics modules improved mutation detection accuracy by 39%. Nearly 57% of oncology research organizations integrated cloud-native bioinformatics platforms for real-time collaboration. Multi-omics capabilities expanded by 44% across pharmaceutical companies to support precision medicine initiatives. High-performance computing integration improved sequencing analysis throughput by 33%. Clinical diagnostics adoption increased by 29% because healthcare providers increasingly rely on genomic analytics for disease profiling, rare disease detection, and personalized therapeutic planning.

Bioinformatics Services: Bioinformatics services accounted for nearly 32% market share due to rising outsourcing among pharmaceutical and biotechnology companies. More than 58% of biotechnology startups relied on third-party bioinformatics service providers for genomic interpretation and protein analysis. Outsourced sequencing analysis volumes increased by 41% during 2025 because laboratories aimed to reduce operational costs and improve scalability. Clinical trial data analytics services expanded by 37% globally. More than 49% of pharmaceutical firms outsourced biomarker discovery workflows to specialized computational biology providers. Cloud-based managed analytics services improved processing efficiency by 28%. Demand for contract bioinformatics support increased significantly in oncology, infectious disease research, and agricultural genomics. Service providers also enhanced AI-driven reporting systems, reducing biological data interpretation time by approximately 31%.

By Application

Metabolomics: Metabolomics represented nearly 9% of the bioinformatics market because of increasing demand for biomarker discovery and disease pathway analysis. More than 38% of metabolic disease studies integrated computational metabolomics platforms during 2025. AI-enabled metabolite identification improved analysis accuracy by 27%. Pharmaceutical companies expanded metabolomic profiling projects by 24% for toxicity assessment and therapeutic optimization. Approximately 46% of academic institutions conducting systems biology research utilized metabolomics software tools. Cloud-enabled metabolomic data storage increased by 32%, improving collaborative research efficiency. Growth in diabetes research, cancer metabolism studies, and precision nutrition initiatives continues to strengthen metabolomics applications in computational biology environments.

Molecular Phylogenetics: Molecular phylogenetics accounted for approximately 7% of the bioinformatics market through expanding evolutionary biology and pathogen surveillance applications. More than 4 million pathogen genome sequences were analyzed for evolutionary tracking during 2024. AI-assisted phylogenetic algorithms improved sequence comparison efficiency by 29%. Around 42% of infectious disease monitoring programs adopted computational phylogenetic analysis tools. Public health agencies increased genomic surveillance projects by 36% after global viral outbreak monitoring initiatives intensified. Research institutions utilized cloud phylogenetic platforms to process over 11 terabytes of evolutionary datasets monthly. Bioinformatics integration in biodiversity conservation studies also increased by 21% globally.

Transcriptomics: Transcriptomics represented nearly 16% market share because of increasing RNA sequencing adoption across oncology and immunology research. More than 59% of cancer genomics projects integrated transcriptomic profiling during 2025. RNA sequencing throughput improved by 34%, enabling faster gene expression analysis. Single-cell transcriptomics studies increased by 39% across biotechnology laboratories. AI-supported transcript interpretation platforms reduced analytical errors by 26%. Approximately 47% of pharmaceutical firms adopted transcriptomic analytics to identify therapeutic response biomarkers. Cloud-based RNA analysis pipelines improved workflow efficiency by 31%, while precision medicine initiatives significantly accelerated transcriptomics utilization in disease diagnostics and drug development.

Proteomics: Proteomics held approximately 18% market share due to increasing protein biomarker discovery and structural biology research. More than 52% of pharmaceutical companies integrated proteomics platforms into therapeutic development programs. AI-driven protein modeling systems processed over 8 million protein structures annually during 2025. Protein interaction mapping efficiency improved by 33% through advanced computational analytics. Around 44% of oncology research projects relied on proteomic profiling for personalized treatment strategies. Mass spectrometry data interpretation tools reduced protein identification time by 28%. Academic research institutions expanded proteomics datasets by 36%, particularly in neurological disease and immunotherapy research applications.

Chemoinformatics: Chemoinformatics accounted for nearly 11% market share because pharmaceutical companies increasingly depend on computational chemistry for drug screening. More than 61% of drug discovery pipelines integrated chemoinformatics platforms during 2025. Virtual screening efficiency improved by 37% through AI-assisted molecular modeling. Around 43% of pharmaceutical organizations adopted predictive toxicity analysis software. Compound database management volumes increased by 31%, with millions of chemical structures processed monthly. Cloud-native chemoinformatics tools reduced computational processing costs by 24%. Expansion of precision therapeutics and accelerated pharmaceutical research continues to increase demand for chemoinformatics solutions globally.

Genomics: Genomics dominated the bioinformatics market with approximately 34% share due to rising sequencing activities worldwide. More than 6.3 million next-generation sequencing tests were completed during 2024. Clinical genomics adoption increased by 54% across oncology diagnostics and rare disease research. AI-enabled genome interpretation platforms improved mutation analysis accuracy by 41%. Approximately 68% of pharmaceutical companies utilized genomic analytics for biomarker discovery and targeted therapy development. Cloud genomic databases stored over 45 exabytes of biological information globally. National genomic research programs expanded by 37%, while precision medicine implementation significantly increased demand for computational genomics solutions.

Others: Other applications represented nearly 5% of the bioinformatics market and included agricultural genomics, environmental bioinformatics, microbiome research, and forensic biology. Agricultural genomics projects increased computational biology investment by 29% during 2025. More than 33% of microbiome studies adopted AI-supported biological analytics platforms. Environmental DNA analysis applications expanded by 21% due to biodiversity monitoring initiatives. Forensic sequencing workflows improved identification efficiency by 26% using bioinformatics tools. Public health laboratories also increased pathogen surveillance analytics deployment by 32%. Expansion of interdisciplinary computational biology applications continues to diversify bioinformatics demand globally.

Bioinformatics Market Regional Outlook

Download Free Sample to learn more about this report.

North America

North America accounted for approximately 39% of the bioinformatics market during 2025 due to strong biotechnology infrastructure and extensive genomic research activities. The United States represented nearly 82% of regional demand because more than 4.2 million genome sequencing tests were conducted annually. Around 71% of precision medicine programs in the region integrated bioinformatics analytics tools. Canada increased public genomic research investment by 26%, while over 63% of oncology hospitals implemented genomic interpretation software. AI-driven protein analysis platforms processed more than 3 million biological datasets annually across North American laboratories.

More than 58% of pharmaceutical companies in North America adopted cloud-native bioinformatics systems to accelerate drug discovery and biomarker analysis. Sequencing turnaround time improved by 31% due to high-performance computing integration. Approximately 49% of healthcare organizations implemented AI-supported diagnostic analytics platforms for rare disease identification. National genomic databases stored over 18 exabytes of biological information in regional research centers. Academic institutions expanded computational biology research programs by 34%, while clinical trial analytics utilization increased by 27%. Expansion of personalized medicine and precision oncology continues to strengthen the regional bioinformatics industry significantly.

Europe

Europe represented nearly 28% of the global bioinformatics market due to strong pharmaceutical manufacturing, government-supported genomic projects, and increasing AI integration in healthcare research. Germany, the United Kingdom, and France collectively contributed over 61% of regional computational biology demand during 2025. More than 52% of European biotechnology companies implemented cloud-based genomic analytics systems. Public health sequencing projects increased by 29% across the region to improve infectious disease monitoring and rare disease diagnostics.

Over 44% of pharmaceutical research centers in Europe adopted multi-omics bioinformatics platforms for drug development. Genome sequencing activities increased by 33% between 2023 and 2025. Around 47% of hospitals involved in oncology diagnostics integrated genomic interpretation software into clinical workflows. AI-supported biomarker discovery tools improved analysis efficiency by 26% in European research institutions. National genomic initiatives expanded database storage capacity by 37%, supporting millions of sequencing records annually. More than 35% of regional research collaborations focused on precision medicine and transcriptomics applications. Increasing regulatory support for personalized healthcare continues driving demand for bioinformatics platforms across Europe.

Asia-Pacific

Asia-Pacific accounted for approximately 24% of the bioinformatics market and demonstrated the fastest infrastructure expansion during 2025. China, Japan, India, and South Korea represented more than 73% of regional genomic research activity. China processed over 1.8 million genome sequencing datasets annually, while India increased biotechnology research funding by 31%. More than 48% of regional pharmaceutical companies adopted AI-enabled bioinformatics platforms for drug discovery and molecular modeling.

Cloud-based sequencing analytics adoption increased by 42% across Asia-Pacific research laboratories. Around 54% of hospitals involved in cancer diagnostics implemented genomic interpretation systems. Academic institutions expanded transcriptomics and proteomics projects by 36% between 2023 and 2025. National healthcare digitization programs accelerated bioinformatics integration across clinical diagnostics and infectious disease monitoring. Approximately 46% of biotechnology startups invested in multi-omics research capabilities. Public genomic surveillance systems analyzed over 6 million pathogen sequences across the region. Increasing precision medicine awareness, rising biotechnology manufacturing capacity, and expansion of AI-powered healthcare infrastructure continue driving strong bioinformatics demand across Asia-Pacific economies.

Middle East & Africa

Middle East & Africa represented approximately 9% of the bioinformatics market during 2025 due to increasing healthcare modernization and genomic disease research initiatives. The United Arab Emirates, Saudi Arabia, and South Africa accounted for nearly 64% of regional computational biology adoption. Government-supported genome sequencing programs increased by 27% across the region. More than 38% of regional hospitals integrated bioinformatics analytics into oncology diagnostics and infectious disease monitoring.

Cloud-based bioinformatics platform adoption increased by 24% because healthcare organizations expanded digital infrastructure investments. Around 33% of pharmaceutical research laboratories implemented AI-assisted molecular analysis systems. National pathogen surveillance projects processed more than 2 million sequencing datasets annually. Academic research collaborations in genomics and proteomics increased by 29% between 2023 and 2025. Approximately 41% of regional biotechnology initiatives focused on precision medicine and hereditary disease analysis. Computational biology training programs also expanded by 22% to address workforce shortages. Increasing public healthcare digitization and rising genomic research investments continue to support gradual bioinformatics market growth across Middle East & Africa.

List of Top Bioinformatics Companies

• Illumina
• Thermo Fisher Scientific
• Agilent Technologies
• QIAGEN
• Eurofins Scientific
• Tempus
• BGI
• Genedata
• Seven Bridges Genomics
• Wuxi NextCODE
• DNAnexus
• Oxford Gene Technology
• Codexis
• Interpace Diagnostics
• Biomax Informatics AG
• Genomatrix (Intrexon)
• Fabric Genomics
• Genoox

Top Two Companies by Market Share

• Illumina held approximately 18% market share in sequencing-driven bioinformatics integration during 2025, supported by more than 25,000 installed sequencing systems globally and over 20 billion genomic reads processed weekly.
• Thermo Fisher Scientific accounted for nearly 14% market share due to expansion in cloud bioinformatics solutions, genomic analytics platforms, and adoption across more than 9,000 biotechnology and pharmaceutical laboratories worldwide.

Investment Analysis and Opportunities

Investment activity in the bioinformatics market increased substantially during 2025 due to expanding precision medicine and AI-enabled healthcare analytics. More than 61% of biotechnology investors prioritized genomic analytics and multi-omics platforms. Venture capital funding for AI-supported computational biology startups increased by 34% between 2023 and 2025. Cloud bioinformatics infrastructure investments expanded by 42% because laboratories increasingly require scalable genomic data processing systems. Pharmaceutical companies allocated approximately 48% higher budgets toward biomarker discovery and sequencing analytics integration.

Government-backed genomic research programs also accelerated investment opportunities. More than 29 countries expanded national genome sequencing initiatives during 2025. Public health organizations invested heavily in pathogen surveillance systems capable of processing millions of genomic records annually. Approximately 46% of healthcare technology partnerships focused on AI-powered molecular diagnostics and predictive disease analytics. Precision oncology research collaborations increased by 31% globally. Agricultural genomics investment also expanded by 27% to improve crop genetics and food sustainability. Emerging opportunities are particularly strong in cloud-native bioinformatics services, AI-driven proteomics, decentralized genomic databases, and automated sequencing analytics. Rising demand for personalized medicine, rare disease diagnostics, and computational drug discovery continues to attract strategic investment across biotechnology ecosystems worldwide.

New Product Development

Manufacturers in the bioinformatics market are focusing heavily on AI-enabled analytics, cloud deployment, and real-time genomic interpretation platforms. During 2025, more than 44% of product launches included machine learning integration for predictive genomic analysis. Automated sequencing pipelines improved biological data processing speed by 36%. Several biotechnology companies introduced multi-omics platforms capable of simultaneously analyzing genomic, transcriptomic, and proteomic datasets. Cloud-native genomic databases increased storage efficiency by 33% compared to traditional on-premise systems.

More than 39% of newly introduced bioinformatics tools supported decentralized laboratory collaboration through remote analytics integration. Real-time pathogen surveillance platforms processed over 1 million genomic records per day in infectious disease research environments. AI-assisted protein structure modeling software reduced computational interpretation time by 28%. Approximately 52% of pharmaceutical organizations adopted newly launched biomarker discovery platforms optimized for precision oncology applications. Advanced visualization dashboards capable of handling billions of genomic data points improved research efficiency by 31%. Companies also introduced cybersecurity-focused genomic data management systems to address privacy concerns in cloud environments. Product development trends continue emphasizing faster analytics, AI automation, and scalable biological data integration.

Five Recent Developments (2023-2025)

• In 2025, Illumina expanded AI-powered sequencing analytics capabilities, improving genomic interpretation throughput by 35% across high-volume clinical laboratories.
• In 2024, QIAGEN introduced an upgraded cloud bioinformatics workflow platform supporting over 12,000 simultaneous genomic analyses daily.
• In 2025, Thermo Fisher Scientific enhanced multi-omics analytics integration, reducing sequencing data processing time by 29% for pharmaceutical research clients.
• In 2023, DNAnexus expanded secure genomic cloud infrastructure capacity by 41% to support large-scale precision medicine initiatives.
• In 2024, Tempus increased AI-enabled oncology analytics deployment by 33%, supporting genomic interpretation across more than 50 healthcare research partnerships.

Report Coverage of Bioinformatics Market

The bioinformatics market report provides detailed analysis of computational biology technologies, genomic analytics platforms, sequencing software, and cloud-based biological data management systems. The report evaluates more than 18 major companies operating across biotechnology, pharmaceutical, healthcare, and academic research sectors. It includes quantitative assessment of genomic sequencing adoption, AI-enabled analytics integration, multi-omics research expansion, and clinical diagnostics implementation trends. Over 45 exabytes of biological information generated globally during 2025 were analyzed within the market scope.

The report covers segmentation by type, including knowledge management tools, bioinformatics platforms, and bioinformatics services. Application analysis includes genomics, proteomics, transcriptomics, metabolomics, chemoinformatics, molecular phylogenetics, and other emerging computational biology fields. Regional evaluation spans North America, Europe, Asia-Pacific, and Middle East & Africa, covering biotechnology infrastructure, genomic research initiatives, and healthcare digitization trends. More than 70 statistical indicators related to sequencing throughput, cloud adoption, AI integration, biomarker discovery, and precision medicine deployment are included. The report also examines investment patterns, product development strategies, technological innovations, regulatory trends, and competitive market positioning shaping the global bioinformatics industry.